Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Growth Hormone Deficiency

In brief

The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.

Key facts

Study ID
NCT01775358
Run by
Aileron Therapeutics, Inc.
People needed
33
Starts
2013-01-01
Expected to finish
2013-05-01
Last updated by the study team
2013-05-30

Who can join

Age: 20 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.